Table 1.
Study cohort Düsseldorf.
| Parameter | Study cohort |
|---|---|
| BTC patients | n = 76 |
| sex (%) | |
| male | 48.7 (37) |
| female | 51.3 (39) |
| Age (years, median and range) | 68.5 (41–89) |
| BMI (kg/m2, median and range) | 26.08 (15.96–44.26) |
| Tumor localization (%) | |
| iCCA | 68.4 (52) |
| Klatskin | 11.8 (9) |
| dCCA | 3.9 (3) |
| gallbladder | 15.8 (12) |
| Staging (%) | |
| UICC I | 26.3 (20) |
| UICC II | 28.9 (22) |
| UICC III | 23.7 (18) |
| UICC IV | 18.4 (14) |
| ECOG PS (n, %) | |
| 0 | 59 (77.6) |
| 1 | 9 (11.8) |
| 2 | 4 (5.3) |
| unknown | 4 (5.3) |
| Chemotherapy (n, %) | |
| neoadjuvant | 4 (5.3) |
| adjuvant | 21 (27.6) |
| Surgical procedure (n, %) | |
| Hemihepatectomy | 14 (18.42) |
| Extended hemihepatectomy | 9 (11.84) |
| Segment resection | 35 (46.05) |
| Whipple / PPPD | 4 (5.26) |
| CHE | 1 (1.32) |
| Whipple + segment resection | 3 (3.95) |
| Hemihepatectomy + segment resection | 2 (2.63) |
| Bile duct resection | 1 (1.32) |
| Other | 7 (9.21) |
| Overall survival (days, median and range) | 527 (2–3087) |
| Recurrence free survival at 12 months (%) | 34.2% (26) |
| Bone mineral density L1 (HU, median and range) | 130 (51.65–253) |
BTC biliary tract cancer, iCCA intrahepatic cholangiocellular adenocarcinoma, dCCA distal cholangiocellular adenocarcinoma, UICC Union for International Cancer Control, ECOG PS Eastern Cooperative Oncology Group Performance Status.